

CURRICULUM VITAE

March 2022

Jeanne Marie Madden

Associate Professor

Department of Pharmacy and Health Systems Sciences
School of Pharmacy and Pharmaceutical Sciences
Bouvé College of Health Sciences
Northeastern University

360 Huntington Ave
R218X TF
140 The Fenway
Boston, Massachusetts 02115
(617) 373-8344
j.madden@northeastern.edu

Education

Ph.D.	Health Policy	Harvard University
Sc.M.	Public Health	Harvard School of Public Health
A.B.	History (magna cum laude)	Brown University

Post-Doctoral Training

Post-Doctoral Fellowship	Harvard Medical School and Harvard Pilgrim Health Care Institute
--------------------------	--

Current Academic Appointments

Associate Professor	Pharmacy and Health Systems Sciences	School of Pharmacy and Pharmaceutical Sciences, Bouvé College of Health Sciences, Northeastern University
Lecturer	Population Medicine	Harvard Medical School and Harvard Pilgrim Health Care Institute

Refereed Articles

“*” indicates Northeastern University student author

1. **Madden JM**, Bayapureddy S*, Briesacher BA, Zhang F, Ross-Degnan D, Soumerai SB, Gurwitz JH, Galbraith AA. Affordability of Medical Care Among Medicare Enrollees. *JAMA Health Forum*, 2021, 2(12), pp. e214104-e214104.
2. Lu CY, Zhang F, Wallace J, LeCates R, Busch AB, **Madden JM**, Callahan MX, Foxworth P, Soumerai SB, Ross-Degnan D, Wharam JF. High-deductible health plans paired with health-savings accounts increased medication cost burden among individuals with bipolar disorder. 2022 (in press at *Journal of Clinical Psychiatry*).
3. Lu CY, Busch AB, Zhang F, **Madden JM**, Callahan MX, LeCates R, Wallace J, Foxworth P, Soumerai SB, Ross-Degnan D, Wharam JF. Impact of high-deductible health plans on medication use among individuals with bipolar disorder. *Psychiatric Services*, 2021,72(8), pp.926-934.
4. Wharam JF, Wallace J, LeCates R, **Madden JM**, Zhang F, Ross-Degnan D, Lu CY. Out-of-pocket spending inequity among high-deductible health plan members with bipolar disorder. *Journal of General Internal Medicine*, online April 2021.
5. **Madden JM**, Araujo-Lane C, Foxworth P, Lu CY, Wharam JF, Busch AB, Callahan MX, Soumerai SB, Ross-Degnan R. Healthcare cost-sharing experiences of people with bipolar disorder in employer plans. *Journal of Affective Disorders*, 2021, 281, pp.41-50.
6. Nekui F*, Soumerai SB, Galbraith AA, Briesacher BA, Zhang F, Ross-Degnan D, Gurwitz JH, **Madden JM**. Cost-related medication nonadherence and its risk factors among Medicare beneficiaries. *Medical Care*, 2021, 59(1), pp.13-21.
7. **Madden JM**, Foxworth P, Ross-Degnan D, Allen K, Busch AB, Callahan MX, Lu CY, Wharam JF. Integrating stakeholder engagement with claims-based research on health insurance design and bipolar disorder. *Psychiatric Services*, 2021, 72(2), pp.186-194.
8. Wharam JF, Busch AB, **Madden JM**, Zhang F, Callahan MX, LeCates R, Foxworth P, Wallace J, Soumerai SB, Ross-Degnan D, Lu CY. Effect of high-deductible insurance on mental health outpatient care in bipolar disorder. *American Journal of Managed Care*, 2020, 26(6), pp.248-255.
9. **Madden JM**, Shetty PS*, Briesacher BA, Zhang F, Ross-Degnan D, Soumerai SB, Gurwitz JH, Galbraith AA. Risk factors associated with food insecurity in the Medicare population. *JAMA Internal Medicine*, 2020, 180(1), pp.144-147.
10. Lu CY, Penfold RB, Toh D, Sturtevant JL, **Madden JM**, Simon G, Ahmedani BK, Clarke G, Coleman KJ, Copeland LA, Daida YG, Davis R, Hunkeler E, Owen-Smith AA, Raebel MA, Rossom R, Soumerai SB, Kuldorff M. Near real-time surveillance for the early detection of health outcomes of FDA warnings using sequential analysis. *Medical Care*, 2018, 56(5), pp.365-372.
11. Adams AS, **Madden JM**, Zhang F, Lu CY, Ross-Degnan D, Lee A, Soumerai SB, Gilden DM, Chawla N, Griggs JJ. Effects of transitioning to Medicare Part D on access to drugs for medical conditions among dual enrollees with cancer. *Value in Health*, 2017, 20(10), pp.1345-1354.

12. **Madden JM**, Lakoma MD, Lynch FL, Rusinak D, Owen-Smith AA, Coleman KJ, Quinn VP, Yau VM, Qian YX, Croen LA. Psychotropic medication use among insured children with autism spectrum disorder. *Journal of Autism and Developmental Disorders*, 2017, 47(1), pp. 144–154.
13. **Madden JM**, Lakoma MD, Rusinak D, Lu CY and Soumerai, S.B., 2016. Missing clinical and behavioral health data in a large electronic health record (EHR) system. *Journal of the American Medical Informatics Association*, 2016, 23(3), pp. 1143–1149.
14. Burns ME, Huskamp HA, Smith JC, **Madden JM**, Soumerai SB. The effects of the transition from Medicaid to Medicare on health care use for adults with mental illness. *Medical Care*, 2016, 54(9) pp. 868–877.
15. Cummings JR, Lynch FL, Rust KC, Coleman KJ, **Madden JM**, Owen-Smith AA, Yau VM, Qian YX, Pearson KA, Crawford PM, Massolo ML, Quinn VP, Croen LA. Health services utilization among children with and without autism spectrum disorders. *Journal of Autism and Developmental Disorders*, 2016, 46(3), pp.910-920.
16. Briesacher BA, **Madden JM**, Zhang F, Fouayzi H, Ross-Degnan D, Gurwitz JH, Soumerai SB. Did Medicare Part D affect national trends in health outcomes or hospitalizations?: A time-series analysis. *Annals of Internal Medicine*, 2015, 162(12), pp.825-833.
17. Coleman KJ, Lutsky MA, Yau V, Qian Y, Pomichowski ME, Crawford PM, Lynch FL, **Madden JM**, Owen-Smith A, Pearson JA, Pearson KA, Rusinak D, Quinn VP, Croen LA. Validation of autism spectrum disorder diagnoses in large healthcare systems with electronic medical records. *Journal of Autism and Developmental Disorders*, 2015, 45(7), pp.1989-1996.
18. Adams AS, Soumerai SB, Zhang F, Gilden DM, Burns ME, Huskamp HA, Trinacty CM, Alegria M, Lecates RF, Griggs J, Ross-Degnan D, **Madden JM**. Effects of eliminating drug caps on racial differences in antidepressant use among dual enrollees with diabetes and depression. *Clinical Therapeutics*, 2015, 37(3), pp.597-609.
19. **Madden JM**, Adams AS, LeCates RF, Ross-Degnan D, Zhang F, Huskamp HA, Gilden DM, Soumerai SB. Changes in drug coverage generosity and untreated serious mental illness: Transitioning From Medicaid to Medicare Part D. *JAMA Psychiatry*, 2015;72(2):179-188.
20. Naci H, Soumerai SB, Ross-Degnan D, Zhang F, Briesacher BA, Gurwitz JH, **Madden JM**. Persistent medication affordability problems among disabled Medicare beneficiaries, 2006-2011. *Medical Care*, 2014, 52(11): 951-6.
21. Naci H, Soumerai SB, Ross-Degnan D, Zhang F, Briesacher BA, Gurwitz JH, **Madden JM**. Medication affordability gains following Medicare Part D are eroding among elderly with multiple chronic conditions. *Health Affairs*, 2014, 33(8): 1435-43.
22. Lu CY, Zhang F, Lakoma MD, **Madden JM**, Rusinak D, Penfold RB, Simon G, Ahmedani BK, Clarke G, Hunkeler E, Waitzfelder B, Owen-Smith A, Raebel MA, Rossom R, Coleman KJ, Copeland LA, Soumerai SB. Changes in youth antidepressant use and suicidal behavior following FDA warnings and media coverage. *British Medical Journal*, 2014; 348: g3596.
23. Adams AS, **Madden JM**, Zhang F, Soumerai SB, Gilden D, Griggs J, Trinacty CM, Bishop C, Ross-Degnan D. Changes in use of lipid-lowering medications among black and white

- dual enrollees with diabetes transitioning from medicaid to Medicare Part D drug coverage. *Medical Care*, 2014, 52(8): 695-703.
24. Burns ME, Busch AB, **Madden JM**, LeCates R, Zhang F, Adams AS, Ross-Degnan D, Soumerai SB, Huskamp HA. Effects of Medicare Part D on guideline-concordant pharmacotherapy for bipolar I disorder among dual beneficiaries. *Psychiatric Services*, 2014, 65(3), pp. 323-329.
 25. Lu CY, Stewart C, Ahmed AT, Ahmedani BK, Coleman K, Copeland LA, Hunkeler E, Lakoma MD, **Madden JM**, Penfold RB, Rusinak D. How complete are E-codes in commercial plan claims databases? *Pharmacoepidemiology and Drug Safety*, 2014, 23(2), p.218.
 26. Penfold RB, Stewart C, Hunkeler EM, **Madden JM**, Cummings JR, Owen-Smith AA, Rossom RC, Lu CY, Lynch FL, Waitzfelder BE, Coleman KJ, Ahmedani BK, Beck AL, Zeber JE, Simon GE. Use of antipsychotic medications in pediatric populations: What do the data say? *Current Psychiatry Reports*, 2013, 15:426
 27. Blanchard J, **Madden JM**, Ross-Degnan D, Soumerai SB. The relationship between emergency department use and cost-related medication nonadherence among Medicare beneficiaries. *Annals of Emergency Medicine*, 2013, 62(5), pp. 475-485.
 28. Harrold L, Briesacher B, Peterson D, Beard A, **Madden JM**, Zhang F, Gurwitz J, Soumerai S. Cost-related medication nonadherence in older patients with rheumatoid arthritis. *Journal of Rheumatology*, 2013, 40(2), pp 137-143.
 29. Nekhlyudov L, **Madden JM**, Graves AJ, Zhang F, Soumerai SB, Ross-Degnan D. Cost-related medication nonadherence and cost-saving strategies used by elderly Medicare cancer survivors. *Journal of Cancer Survivorship*, 2011;5(4), pp. 395-404.
 30. Briesacher BA, Zhao Y, **Madden JM**, Zhang F, Adams AS, Tjia J, Ross-Degnan D, Gurwitz JH, Soumerai S. Medicare Part D and changes in prescription drug use and cost burden: National estimates for the Medicare population, 2000-2007. *Medical Care*, 2011, 49(9) pp. 834-841.
 31. Sawicki GS, Vilck Y, Schatz MX, Kleinman K, Abrams A, **Madden JM**. Uncontrolled asthma in a commercially insured population from 2002 to 2007: Trends, predictors, and costs. *Journal of Asthma*. 2010, 47(5), pp. 574-80.
 32. **Madden JM**, Meza E, Ewen M, Laing RO, Stephens P, Ross-Degnan D. Measuring medicine prices in Peru: validation of key aspects of WHO/HAI survey methodology. *Pan-American Journal of Public Health*. 2010, 27(4), pp. 291-9.
 33. Zivin K, **Madden JM**, Graves AJ, Zhang F, Soumerai SB. Cost-related medication nonadherence among beneficiaries with depression following Medicare Part D. *American Journal of Geriatric Psychiatry*, 2009, 17(12), pp. 1068-76.
 34. **Madden JM**, Graves AJ, Ross-Degnan D, Briesacher B, Zhang F, Adams AS, Gurwitz JH, Adler GS, Soumerai SB. Cost-related medication nonadherence after implementation of Medicare Part D 2006-2007. *Journal of the American Medical Association*, 2009, 302(16), pp. 1755-6.
 35. **Madden JM**, Graves AJ, Zhang F, Adams AS, Briesacher BA, Ross-Degnan D, Gurwitz JH, Pierre-Jacques M, Safran DG, Adler GS, Soumerai SB. Cost-related medication

nonadherence and spending on basic needs following implementation of Medicare Part D. *Journal of the American Medical Association*, 2008, 299(16), pp 1922-1928.

36. **Madden JM**, Soumerai SB, Lieu TA, Mandl KD, Zhang F, Ross-Degnan D. Length-of-stay policies and ascertainment of postdischarge problems in newborns. *Pediatrics*, 2004, (113) pp 42-49.
37. Sinha A, **Madden JM**, Ross-Degnan D, Soumerai SB, Platt R. Reduced risk of neonatal respiratory infections among breastfed girls but not boys. *Pediatrics*, 2003, 112(4), pp. e303-e308.
38. **Madden JM**, Soumerai SB, Lieu TA, Mandl KD, Zhang F, Ross-Degnan D. Effects on breastfeeding of changes in maternity length-of-stay policy in a large health maintenance organization. *Pediatrics*, 2003, 111(3), pp. 519-24.
39. **Madden JM**, Soumerai SB, Lieu TA, Mandl KD, Zhang F, Ross-Degnan D. Effects of a law against early postpartum discharge on newborn follow-up, adverse events, and HMO expenditures. *New England Journal of Medicine*, 2002, 347(25), pp. 2031-8.
40. **Madden JM**, Quick JD, Ross-Degnan D, Kafle KK. Undercover careseekers: Simulated clients in the study of health provider behavior in developing countries. *Social Science and Medicine*, 1997, 45(10), pp. 1465-82.
41. Kafle KK, **Madden JM**, Shrestha AD, Karkee SB, Das PL, Pradhan YM, Quick JD. Can licensed drug sellers contribute to safe motherhood? A survey of the treatment of pregnancy-related anaemia in Nepal. *Social Science and Medicine*, 1996, 42(11), pp. 1577-88.

Non-Refereed Articles

1. **Madden JM**. Three Decades of Drug Cap Studies Are Enough (invited commentary). *JAMA Health Forum*, 2021, 2(6), p. e211249.
2. **Madden JM**. Basic results that the WHO/HAI survey offers country-level investigators. *Essential Drugs Monitor*, 2003, (33), pp. 15-16.
3. **Madden JM**, Kotwani A. Availability of essential medicines: an example from Rajasthan, India. *Essential Drugs Monitor*, 2003, (33), p.17.
4. **Madden JM**, Balasubramaniam K, Kibwage I. Components of patient prices: examples from Sri Lanka and Kenya. *Essential Drugs Monitor*. 2003, (33), p.18.
5. **Madden JM**. Comparing pilot survey results from different countries. *Essential Drugs Monitor*, 2003, (33), pp.19-20.

MyBibliography: <https://www.ncbi.nlm.nih.gov/myncbi/1diXzv-Qxo05W/bibliography/public/>